New antibiotics for selective treatment of gastrointestinal infection caused byClostridium difficile

National point prevalence of Clostridium difficile in US health care facility inpatients, 2008

(2009) William R. Jarvis et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study

(2009) Daniel M. Musher et al.   CLINICAL INFECTIOUS DISEASES

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections

(2009) I. A. Critchley et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria

(2009) D. M. Citron et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model

(2009) U. A. Ochsner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses

(2008) Y. K. Shue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rising Economic Impact of Clostridium difficile-Associated Disease in Adult Hospitalized Patient Population

(2008) Xiaoyan Song et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin

(2008) R. O'Connor et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?

(2008) J. M. Blondeau   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A case-control study of community-associated Clostridium difficile infection

(2008) M. H. Wilcox et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY